Dr. Salim Hayek is the Medical Director of the Michigan Medicine Frankel Cardiovascular Center Clinics and an Assistant Professor of Internal Medicine and Cardiovascular Medicine at the University of Michigan in Ann Arbor.
Dr. Hayek is a National Institute of Health-funded physician-scientist, with expertise in biomarker and risk prediction research. While early in his career, he has authored over 100 peer-reviewed publications, many in the highest impact journals such as the New England Journal of Medicine, the British Medical Journal, Nature Medicine, Circulation, Circulation Research, the Journal of the American Society of Nephrology and others. He has many accolades and awards for both excellence in patient care and his contributions to science, including the American College of Cardiology Douglas P. Zipes Distinguished Young Scientist award and the American Heart Association Samuel Levine Early Career Investigator award.
His most notable contribution to research to date has been his characterization of soluble urokinase plasminogen activator receptor (suPAR) as a pathogenic factor and a druggable target in kidney disease. His current focus is on the identification of anti-suPAR therapies and the incorporation of biomarkers in cardiovascular disease management, research that has the promise of greatly improving identification and treatment of kidney disease among cardiovascular patients.
Dr. Hayek completed his Internal Medicine and Cardiology training at Emory University in Atlanta GA. He moved to Ann Arbor in 2018 to join the University of Michigan Frankel Cardiovascular Center where he practices Cardio-Oncology and has established a thriving Biomarkers Laboratory. He continues to pursue state of the art research in biomarkers and risk prediction, leveraging the University of Michigan vast research infrastructure.